Skip to main content

Noninvasive Endometriosis Test Developer DotLab Secures $10M in Series A Funding

NEW YORK – Women's health personalized medicine company DotLab said on Monday it has secured $10 million in Series A funding.

The San Francisco-based firm is combining noninvasive microRNA biomarkers with machine learning to develop a noninvasive test for endometriosis. In a statement, DotLab CEO Heather Bowerman said that the company will use the funds to "further clinical validation, expand market access, and continue to grow our team."

CooperSurgical, a business unit of The Cooper Companies, led the financing, which also included individual investors from Tiger Global Management, Luxor Capital Group, and the law firm Wilson Sonsini Goodrich & Rosati.

The DotLab test detects microRNA biomarkers, but it is not a genetic test for endometriosis, and the risk profiles do not confirm active disease, Bowerman said in an email.